TARS — Tarsus Pharmaceuticals, Inc. stock price, charts and financials

QT64Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
79.03
+1.39+1.79%
OverviewShort InterestFilings
TARSQT64Tarsus Pharmaceuticals, Inc.·NASDAQ
79.03+1.79%
News
Up 1.8% — Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target (Benzinga).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
VKTX-0.54%$29.36DYN+4.33%$18.06ARQT+1.22%$26.46LEGN+3.41%$17.58ELVN+2.28%$50.24RCUS+3.61%$25.54DNLI+0.35%$20.13IDYA+2.33%$38.61
Snapshot
Index-P/E-EPS (ttm)-1.09Insider Own4.73%Shs Outstand43.02MPerf Week-2.58%
Market Cap3.40BForward P/E52.51EPS next Y1.51Insider Trans-5.18%Shs Float40.39MPerf Month11.26%
Enterprise Value3.04BPEG-EPS next Q-1.58Inst Own-Short Float14.88%Perf Quarter26.35%
Income-47.00MP/S5.60EPS this Y-90.02%Inst Trans-Short Ratio6.32Perf Half Y15.81%
Sales607.00MP/B9.80EPS next Y172.66%ROA-7.60%Short Interest6.01MPerf YTD-3.48%
Book/sh8.07P/C7.56EPS next 5Y-ROE-13.53%52W High91.53 -13.66%Perf Year56.19%
Cash/sh10.46P/FCF55.44EPS past 3/5Y-ROIC-11.15%52W Low50.71 55.85%Perf 3Y381.01%
Dividend Est.-EV/EBITDA-Sales past 3/5Y158.86% -Gross Margin90.59%Volatility3.35% 4.21%Perf 5Y243.61%
Dividend TTM-EV/Sales5.01EPS Y/Y TTM64.50%Oper. Margin-8.00%ATR (14)3.33Perf 10Y-
Dividend Ex-Date-Quick Ratio3.17Sales Y/Y TTM231.69%Profit Margin-7.67%RSI (14)56.40Recom2.00
Dividend Gr. 3/5Y-Current Ratio3.20EPS Q/Q10.42%SMA201.77%Beta0.44Target Price100.40
Payout0.00%Debt/Eq0.27Sales Q/Q68.93%SMA5015.39%Rel Volume0.42Prev Close77.64
Employees370LT Debt/Eq0.27EarningsNov 03SMA20014.86%Avg Volume1.01MPrice79.03
IPO DateOct 16, 2020Option/ShortYes / YesEPS/Sales Surpr.-124.23% 2.51%Net Debt/EBITDA3.29Volume426,957Change1.79%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-16-26ReiteratedBarclaysOverweight$100 → $110
Sep-08-26ReiteratedJefferiesBuy$58 → $105
Aug-12-26ReiteratedOppenheimerOutperform$72 → $100
Jul-31-26ReiteratedMizuhoOutperform$100 → $98
Jul-21-26ReiteratedGuggenheimBuy$84 → $89
Feb-05-26ReiteratedGoldman SachsNeutral$51 → $68
Dec-08-25InitiatedBarclaysOverweight$62 → $100
Nov-20-25InitiatedMizuhoOutperform$100
Nov-06-25ReiteratedGoldman SachsNeutral$45 → $51
Oct-20-25ReiteratedHC Wainwright & Co.Buy$61 → $88
Latest News· Times ET
Sep-16-26
Sep-16-2604:56AM
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price TargetBenzinga
Sep-08-26
Sep-08-2610:50AM
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105Benzinga
Sep-04-26
Sep-04-2604:38AM
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Careglobenewswire.com
Sep-03-26
Sep-03-2611:27PM
114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corpdefenseworld.net
07:10AM
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Diseaseglobenewswire.com
Sep-01-26
Sep-01-2612:30PM
Tarsus to Participate in Upcoming Investor Conferencesglobenewswire.com
Aug-24-26
Aug-24-2604:31AM
Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt DiseaseBenzinga
04:30AM
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Diseaseglobenewswire.com
Aug-12-26
Aug-12-2607:16AM
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100Benzinga
Aug-07-26
Aug-07-2609:06AM
Tarsus Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2601:41PM
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M EstimateBenzinga
10:54AM
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcriptseekingalpha.com
05:21AM
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimateszacks.com
03:03AM
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growthglobenewswire.com
03:02AM
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financingglobenewswire.com
Company

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue607451183——————
Cost of Goods Sold Incl. D&A573113——————
Gross Profit550421170——————
Selling, General and Administrative Excl. Other527427237——————
Research and Development876453——————
Other Operating Expense-1511——————
Operating Income-49-71-121——————
Interest Expense897——————
Unusual Expense
—————————
Non-Operating Income (Expense)131612——————
Net Income Before Taxes-44-64-116——————
Income Taxes320——————
Consolidated Net Income-47-66-116——————
Net Income From Continuing Operations-47-66-116——————
Net Income-47-66-116——————
EPS (Recurring)-1.09-1.59-3.07——————
EPS (Basic, Before Extraordinaries)-1.09-1.59-3.07——————
EPS (Diluted)-1.09-1.59-3.07——————
EBITDA-36-54-106——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio5.607.6311.50——————
Gross Margin90.6193.3592.90——————
Operating Margin-8.07-15.74-66.12——————
Net Margin-7.74-14.63-63.39——————
Shares Outstanding434238——————
Market Capitalization3,3983,4392,104——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$98.57$81.69$64.80$47.91$31.03● Close Price0.00M1.98M3.97M5.95M7.94MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
PYOTT DAVID E IDirectorSep 15 '26Option Exercise0.0020109,575Sep 17
LINK WILLIAM J PHDDirectorSep 15 '26Option Exercise0.002010106,987Sep 17
LINK WILLIAM J PHDDirectorSep 15 '26Sale78.3812,500979,74594,487Sep 17
YARNO WENDY LDirectorSep 15 '26Option Exercise0.00302016,956Sep 17
Neervannan SeshadriChief Operating OfficerSep 04 '26Sale85.004,564387,94078,532Sep 09
Lin Elizabeth YeuChief Medical OfficerSep 04 '26Sale87.5013,9531,220,8851,590Sep 09
Azamian Bobak R.President/CEO and Board ChairSep 04 '26Sale90.5610,000905,600827,991Sep 09
Azamian Bobak R.President/CEO and Board ChairSep 02 '26Sale80.0610,000800,600837,991Sep 03
Lin Elizabeth YeuChief Medical OfficerSep 02 '26Sale80.006,977558,1604,770Sep 03
Lin Elizabeth YeuChief Medical OfficerSep 01 '26Sale73.864,601339,83018,707Sep 03
Azamian Bobak R.President/CEO and Board ChairJun 17 '26Sale61.5510,000615,489847,991Jun 22
Farrow Jeffrey SSee RemarksJun 16 '26Sale60.9514,396877,43656,801Jun 17
Farrow Jeffrey SSee RemarksJun 15 '26Option Exercise0.0027,881071,197Jun 17
Goodrich KatherineDirectorJun 15 '26Sale62.082,954183,3842,233Jun 17
LINK WILLIAM J PHDDirectorJun 15 '26Sale62.1212,500776,495106,786Jun 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.